New combo therapy shows promise for rare, Tough-to-Treat leukemia
NCT ID NCT05901974
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining venetoclax and azacitidine can help people with a rare type of leukemia called acute leukemia of ambiguous lineage. The study will enroll 23 newly diagnosed patients aged 15 and older. The goal is to see if this drug combination can improve remission rates and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and azacitidine
What this could lead to
If this works, it could offer a new, more effective treatment option for people with this rare and aggressive leukemia, potentially improving remission rates.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, China
Contact